Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan.
Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; Department of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan; Institute of Medical Technology, College of Life Science, National Chung-Hsing University, Taichung, Taiwan; School of Medicine, National Defense Medical Center, Taipei, Taiwan.
Clin Chim Acta. 2018 Aug;483:130-134. doi: 10.1016/j.cca.2018.04.032. Epub 2018 Apr 26.
We aimed to examine the association of serum high mobility group box 1 (HMGB1) level with cardiovascular risk in patients undergoing coronary angiography with no history of diabetes.
We enrolled patients with no history of diabetes who had been admitted for coronary angiography due to suspected or known coronary artery disease. Two to four weeks after the patients were discharged from the hospital, an oral glucose tolerance test (OGTT) was conducted and serum HMGB1 level was measured. Patients' 10-year coronary heart disease (CHD) risk was assessed using the Framingham Risk Scoring.
A total of 476 patients were enrolled. Overall, mean serum HMGB1 level was 6.1 ± 1.3 pg/ml. Using linear regression analysis, high-density lipoprotein cholesterol was negatively associated with serum HMGB1 (β coefficient - 0.033, 95% CI -0.063 to -0.003, p = 0.033) after adjustment for several confounders. With regard to cardiovascular risk, levels of serum HMGB1 were positively associated with 10-year CHD risk (β coefficient 0.506, 95% CI 0.030 to 0.983, p = .037), independent of patients' undiagnosed abnormal glucose regulation.
In patients undergoing coronary angiography with no history of diabetes, levels of serum HMGB1 were positively associated with 10-year CHD risk, independent of patients' undiagnosed abnormal glucose regulation.
我们旨在研究在无糖尿病病史的行冠状动脉造影术的患者中,血清高迁移率族蛋白 1(HMGB1)水平与心血管风险的相关性。
我们纳入了因疑似或已知冠状动脉疾病而入院行冠状动脉造影术且无糖尿病病史的患者。患者出院后 2 至 4 周,行口服葡萄糖耐量试验(OGTT)并检测血清 HMGB1 水平。采用弗雷明汉风险评分评估患者的 10 年冠心病(CHD)风险。
共纳入 476 例患者。总体而言,平均血清 HMGB1 水平为 6.1±1.3pg/ml。经线性回归分析,在调整了多种混杂因素后,高密度脂蛋白胆固醇与血清 HMGB1 呈负相关(β系数-0.033,95%置信区间-0.063 至-0.003,p=0.033)。就心血管风险而言,血清 HMGB1 水平与 10 年 CHD 风险呈正相关(β系数 0.506,95%置信区间 0.030 至 0.983,p=0.037),且独立于患者未诊断的异常葡萄糖调节。
在无糖尿病病史的行冠状动脉造影术的患者中,血清 HMGB1 水平与 10 年 CHD 风险呈正相关,且独立于患者未诊断的异常葡萄糖调节。